search
diabetes patients
Trends
- 1Pancreatic Cells One Genetic Tweak From Treating Diabetes▼Some Pancreatic Cells Are Just One Genetic Tweak Away From Treating Diabetes https:// fed.brid.gy/r/https://www.wire d.c
New research suggests some pancreatic cells could be converted into insulin-producing cells with a single genetic modification, offering a promising avenue for diabetes treatment. The findings, reported by Wired, point to the potential of reprogramming existing cells to restore insulin function in patients. Scientists and health watchers are sharing the story as a possible step toward new therapies for the disease.
- 2The End of Insulin Injections? Scientists Push Needle-Free Medicine▼The End of Insulin Injections? How Scientists Are Making Medicine Needle-Free
Scientists are developing needle-free ways to deliver medicine, including insulin, with the goal of replacing traditional injections for millions of patients, particularly people with diabetes. The work, highlighted by National Geographic, covers new technologies that could deliver drugs through the skin or other routes without needles. If successful, the approach could reduce pain and needle anxiety for patients who need daily injections.
- 3Strict blood sugar control may carry hidden costs, study finds●Diabetes study finds keeping blood sugar too steady may come at a price
New research into diabetes suggests that keeping blood sugar levels extremely steady, long considered the gold standard of management, may come with drawbacks. The findings challenge the assumption that tighter is always better for glucose control, prompting debate among clinicians and patients about how aggressively blood sugar should be stabilised and what trade-offs tight control may involve.
- 4Israeli startup wins FDA clearance for injection-based diabetes app●Israeli startup develops injection-based diabetes app, receives FDA clearance
An Israeli startup has received US Food and Drug Administration clearance for an app designed to support people managing diabetes with injections. The digital tool is aimed at helping patients track and handle their insulin treatment more effectively. The clearance marks a regulatory milestone for the young company, and coverage in Israeli media highlights it as another example of the country's health-tech sector gaining traction abroad.
- 5Nutritional Deficiencies Reported in Youth on GLP-1 Drugs▼Nutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists
New reporting highlights that young people taking GLP-1 receptor agonists, a class of drugs widely used for weight management and diabetes, are showing nutritional deficiencies. Clinicians are being advised to monitor nutrient intake in pediatric and adolescent patients on these medications, as appetite suppression may reduce overall consumption of essential vitamins and minerals during critical growth years.
- 6Doctors weigh in on the Ozempic microdosing trend▼Is microdosing Ozempic safe? An obesity medicine doctor on the trend, the risks, and when a low dose makes sense
An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.
- 7FDA approves Onswik, a once-weekly insulin for type 2 diabetes●The FDA approved Onswik, a once-weekly insulin for type 2 diabetes, but not for type 1. What the trials showed and the s
The FDA has approved Onswik, a once-weekly insulin intended for adults with type 2 diabetes. It was not approved for type 1 diabetes. Coverage highlights what the clinical trials showed about effectiveness and the side effects patients should know about. The approval is drawing attention as a potential convenience shift for diabetes management, reducing injections from daily to weekly.